Galena taps Teva to handle global distribution and commercialization of NeuVax; U.K. whooping cough cases are 10 times the number in the last peak;

 @AlisonBFierce: DARPA will try where others have failed. The agency aims to develop a DNA vaccine. More | Follow @AlisonBFierce

> Galena Biopharma ($GALE) announced that Teva Pharmaceutical Industries ($TEVA) will handle global distribution and commercialization of NeuVax. Story

> Whooping cough cases in the U.K. this year are 10 times the number seen in the last peak year for the illness in 2008. Report

> Doctors and scientists say upping the rate of flu vaccinations to 80% could significantly reduce outbreaks or wipe out the virus entirely. Story

> Novavax ($NVAX) published a preclinical efficacy study of its RSV fusion protein nanoparticle vaccine candidate. Release

And Finally... Vical ($VICL) licensed its Vaxfectin adjuvant to Cyvax for use in malaria vaccines. Release

Suggested Articles

CEPI, which started to help prepare the world for new outbreaks, has awarded Inovio and Moderna money for vaccine work against the new coronavirus.

As a new coronavirus spreads, vaccine researchers have started work on candidates against the virus—and one could enter the clinic in a few months.

Merck's HPV vaccine Gardasil is delivering blockbuster sales as demand surges. But high demand has caused somewhat of a supply constraint.